Drug Profile

REGV131 LNP1265

Alternative Names: REGV 131 LNP 1265

Latest Information Update: 03 Oct 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Intellia Therapeutics
Developer Regeneron Pharmaceuticals
Class Antihaemorrhagics; Blood coagulation factors; Gene therapies
Mechanism of Action Factor IX replacements; Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Haemophilia B
New Molecular Entity No

Highest Development Phases

Phase I/II Haemophilia B

Most Recent Events

11 Sep 2024 Phase-I/II clinical trials in Haemophilia B (In adults, In adolescents, In children) in USA (IV) (NCT06379789)
23 Apr 2024 Regeneron Pharmaceuticals plans the phase-I/II BEYOND-9 trial for Haemophilia B (In children, In adolescents, In adults) in July 2024 (IV) (NCT06379789)
31 Mar 2024 Intellia Therapeutics opt-out rights for REGV131 LNP1265

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com